Suggested remit: To appraise the clinical and cost effectiveness of nivolumab with temozolomide and radiotherapy within its marketing authorisation for newly diagnosed MGMT-methylated glioblastoma multiforme.
Following on from information provided to NICE by the company in February 2021, the appraisal of Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1582
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 November 2022 | Note added to the project documents |
| 21 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2021, the appraisal of Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 18 August 2021 | Expected publication |
| 12 February 2021 | Note added to the project documents |
| 12 February 2021 | Suspended. Topic is suspended |
| 21 August 2020 | Note added to the project documents |
| 12 May 2020 | Note added to the project documents |
| 11 December 2019 | Note added to the project documents |
| 16 September 2019 | Note added to the project documents |
| 28 June 2019 | Note added to the project documents |
| 08 May 2019 - 06 June 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 18 April 2018 | In progress. DHSC Referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual